{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.6","upperLimit":"71.4","value":"57.5"},{"groupId":"OG001","lowerLimit":"52.0","upperLimit":"78.6","value":"65.3"},{"groupId":"OG002","lowerLimit":"47.0","upperLimit":"73.6","value":"60.3"},{"groupId":"OG003","lowerLimit":"57.8","upperLimit":"84.0","value":"70.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"56"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate 5-year EFS, defined as the time from study enrollment to disease progression or recurrence, second malignant neoplasm, or death from any cause, or to date of last contact. Estimates are reported with 95% confidence intervals. Data below represents all molecular subgroups combined.","dispersionType":"95% Confidence Interval","groups":[{"description":"Medulloblastoma patients who received regimen A (no carboplatin / no isotretinoin)","id":"OG000","title":"Regimen A (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen B (carboplatin / no isotretinoin)","id":"OG001","title":"Regimen B (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen C (no carboplatin / isotretinoin)","id":"OG002","title":"Regimen C (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen D (carboplatin / isotretinoin)","id":"OG003","title":"Regimen D (Medulloblastoma Patients)"}],"paramType":"NUMBER","populationDescription":"Eligible medulloblastoma patients are included.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percent Probability of Event-free Survival (EFS) for Patients With Medulloblastoma","type":"PRIMARY","unitOfMeasure":"Percent Probability"}